Why Is Replimune Group (REPL) Stock Down -32.1% Today?

Key Takeaways

• REPL shares plummeted approximately 32% on Tuesday, trading near $5.86 after closing the prior session at $8.63.
• The primary catalyst was the release of FDA briefing documents ahead of a July 30 advisory committee meeting, in which agency reviewers cast serious doubt on the efficacy of Replimune's lead cancer drug candidate.
• FDA staff stated the company's data still does not demonstrate substantial evidence of effectiveness, raising concerns about the single-arm trial design and methodology used to assess tumor responses.
• This is Replimune's third attempt at approval for RP1 in advanced melanoma, following Complete Response Letters in July 2025 and April 2026.
• The sell-off extends a brutal five-session losing streak that has now erased roughly 47% of REPL's market value in less than a week.
• Traders are now squarely focused on the July 30 AdCom meeting and the August 2 PDUFA target action date.

Opening Summary

Shares of REPL, the clinical-stage biotechnology company Replimune Group, Inc., collapsed on Tuesday after the U.S. Food and Drug Administration released highly critical briefing documents ahead of a pivotal advisory committee meeting. The stock tumbled roughly 32.1% to trade near $5.86, down from the previous session's close of $8.63. Replimune is seeking accelerated approval of its lead candidate, vusolimogene oderparepvec (RP1), in combination with Bristol Myers Squibb's Opdivo for patients with advanced melanoma. The FDA's blistering assessment of the company's efficacy data has reignited fears that the drug could face a third rejection.

FDA Briefing Documents Deliver a Damaging Assessment

The sell-off was triggered by the release of FDA briefing documents ahead of the advisory committee meeting scheduled for Thursday, July 30. In those documents, agency reviewers concluded that Replimune's resubmitted Biologics License Application "doesn't include an adequate and well-controlled investigation that shows substantial evidence of effectiveness." The FDA further noted that the company's additional exploratory analyses submitted to support an efficacy claim were "not sufficient to resolve the deficiencies" the agency had previously identified.

This assessment represents a significant blow to Replimune's hopes of finally securing approval after an arduous regulatory journey. The FDA specifically raised concerns about the single-arm design of the IGNYTE clinical trial — in which all patients received the experimental drug with no comparison group — and questioned whether the methodology used to assess tumor responses may have overstated both the response rate and the duration of response. Because RP1 is injected directly into tumors, the agency noted that observed tumor shrinkage could reflect a local injection effect rather than a broader systemic anti-cancer benefit.

A Third Attempt at Approval Faces Long Odds

Replimune's pursuit of FDA approval for RP1 has been marked by repeated setbacks. The agency issued its first Complete Response Letter in July 2025, followed by a second rejection in April 2026 — both citing concerns that the clinical data fell short of proving the drug's effectiveness. Following the second rejection, the company took the unusual step of engaging with the White House in early May, arguing that the rejections did not align with the Trump administration's stated desire to help terminally ill patients. The White House subsequently pushed health officials to re-examine the decision.

That political intervention appeared to open a door: in late May, Replimune announced it had reached an agreement with the FDA to resubmit its BLA for a third review, with the agency setting a target action date of August 2 and scheduling an advisory committee meeting for late July. Tuesday's briefing documents, however, suggest the FDA's scientific reviewers have not changed their fundamental view of the data.

Market Context and Trading Activity

Tuesday's plunge did not occur in isolation. REPL shares had already fallen sharply over the preceding four sessions, shedding roughly 20% of their value before Tuesday's dramatic leg lower. The combined five-session decline now approaches 47%, wiping out months of gains that had been built on optimism surrounding the resubmission. Trading volume on Monday exceeded 5.1 million shares — well above the 10-day average — and Tuesday's volume was poised to set a new record as investors rushed for the exits.

The move was largely company-specific rather than sector-driven. Broader biotechnology indices did not experience comparable selling pressure, confirming that REPL's decline was driven by the FDA's stark assessment rather than a rotation out of biotech or risk-off sentiment in the broader market.

Technically, the stock has sliced through multiple support levels, including the psychologically significant $10, $9, $8, $7, and $6 thresholds in rapid succession. The intraday low on the previous session touched $7.37, and Tuesday's trading pushed shares into territory not seen since the depths of the April 2026 sell-off.

What Comes Next for REPL

All eyes now turn to the July 30 advisory committee meeting, where outside experts will review the data and vote on whether they believe RP1's benefits outweigh its risks. While the FDA is not bound by the committee's recommendation, it typically follows the advice of its advisory panels. Given the tone of the briefing documents, the AdCom vote could prove pivotal — and expectations are low.

The FDA's formal target action date is August 2, just days after the advisory committee meeting. If the agency issues a third Complete Response Letter, Replimune would face difficult questions about the path forward for RP1 in melanoma. The company is also advancing a confirmatory Phase 3 trial (IGNYTE-3) and developing its second-generation candidate RP2 in uveal melanoma, but both programs remain in earlier stages. Replimune reported cash and equivalents of $268.9 million as of March 31, 2026 — a runway it estimates will fund operations into early 2027, though a third rejection could accelerate scrutiny of its burn rate.

Trending AI Robots

For investors seeking to navigate volatile market conditions with data-driven precision, Tickeron offers a curated selection of Trending AI Robots. These AI-powered trading bots are designed to scan thousands of tickers across multiple strategies and timeframes, identifying and executing trades based on real-time technical and fundamental signals. Only the strongest-performing bots under current market conditions are featured in the Trending AI Robots section, giving users access to battle-tested automated strategies. Whether markets are surging, selling off, or trading sideways, explore how AI-driven trading can complement your decision-making process by visiting Trending AI Robots to see which strategies are leading the pack today.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Allana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume